


NiCCC


Nintedanib in Clear Cell Carcinoma

A Randomised Phase II Study of BIBF 1120 versus
Chemotherapy in Recurrent Clear Cell Carcinoma of the
Ovary or Endometrium

SGCTG/NCRI/NSGO



NiCCC Trial Design



Primary Endpoint: PFS

Secondary Endpoints: OS, Toxicity, RR, QoL, Q-Twist

Trial Status

- Trial supported by Boehringer Ingelheim and by Cancer Research UK
- Sample collection grant from CTAAC
- Regulatory submissions made in UK